New data presented by Memorial Sloan Kettering at the American Society of Clinical Oncology in Chicago June 4 showed promising results for mesothelioma patients with solid tumors who were given a new immunotherapy from Atara Biotherapeutics. The CAR T therapy targeting mesothelin was delivered along with chemotherapy. The results ”reaffirm mesothelin as a promising target…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
